Impact of Pharmacist-Led Medication Review on Reducing Adverse Drug Events

Authors

  • Dhaifalla M. Moparak Alrwili
  • Mohammed Tajir D Alanazi
  • Muqrin Saeed Hulayyil Almutairi
  • Alharbi Waleed Abdullah M
  • Salam Saud Alanazi
  • Mohammed Hassan Almuntashiri
  • Hussein Fallah Khadran Alrashidi
  • Saleh Abdulkarim A Alkuraya
  • Ahlam Salem Bin Binyah Alanaz
  • Waleed Saud AbdulAziz AlShdokhy
  • Hamdi Ayidh Qidan Albaqami

DOI:

https://doi.org/10.22399/ijcesen.4646

Keywords:

Pharmacist-led medication review, adverse drug events, patient safety, polypharmacy, chronic conditions

Abstract

Pharmacist-led medication reviews play a critical role in optimizing patient safety and minimizing the risk of adverse drug events (ADEs). In a healthcare environment where polypharmacy is prevalent, especially among elderly patients or those with chronic conditions, pharmacists possess the expertise to evaluate medication regimens comprehensively. Through systematic reviews, pharmacists can identify potential drug interactions, duplicate therapies, and inappropriate medication usage, ensuring that patients receive safe and effective treatments. By collaborating with healthcare teams and educating patients about their medications, pharmacists not only mitigate the risk of ADEs but also enhance overall adherence to therapeutic plans, ultimately improving health outcomes. The implementation of pharmacist-led medication reviews has demonstrated tangible reductions in the frequency and severity of ADEs across various healthcare settings. Studies show that when pharmacists conduct thorough medication reconciliations and provide follow-up consultations, patients experience fewer hospitalizations and emergency department visits due to medication-related complications. Furthermore, these reviews contribute to a culture of safety within healthcare systems by fostering communication among healthcare providers and empowering patients to take an active role in their medication management. As such, integrating pharmacist-led initiatives into routine patient care is a strategic approach to enhancing medication safety and achieving better pharmacotherapy outcomes.

References

1. Bond C.M., Fish A., Porteous T.H., Reid J.P., Scott A., Antonazzo E. A Randomised Controlled Trial of the Effects of Note-Based Medication Review by Community Pharmacists on Prescribing of Cardiovascular Drugs in General Practice. International Journal of Pharmacy Practice. 2007;15:39–46.

2. Edwards I.R., Aronson J.K. Adverse Drug Reactions: Definitions, Diagnosis, and Management. The Lancet. 2000;356:1255–1259.

3. Rolfes L., van Hunsel F., Taxis K., van Puijenbroek E. The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands. Drug Safety. 2016;39:769–776.

4. Brajković A., Bosnar L., do Nascimento M.M.G., Prkačin I., Balenović A., Ramalho de Oliveira D., Mucalo I. Healthcare Utilisation and Clinical Outcomes in Older Cardiovascular Patients Receiving Comprehensive Medication Management Services: A Nonrandomised Clinical Study. International Journal of Environmental Research and Public Health. 2022;19:2781.

5. Bladh L., Ottosson E., Karlsson J., Klintberg L., Wallerstedt S.M. Effects of a Clinical Pharmacist Service on Health-Related Quality of Life and Prescribing of Drugs: A Randomised Controlled Trial. BMJ Quality & Safety. 2011;20:738–746.

6. Davies E.C., Green C.F., Taylor S., Williamson P.R., Mottram D.R., Pirmohamed M. Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes. PLoS ONE. 2009;4:e4439.

7. The Croatian Parliament Medicinal Products Act. 2013.

8. Alhawassi T.M., Krass I., Bajorek B.V., Pont L.G. A Systematic Review of the Prevalence and Risk Factors for Adverse Drug Reactions in the Elderly in the Acute Care Setting. Clinical Interventions in Aging. 2014;9:2079–2086.

9. Stephens M.D.B. Definition and Classification of Adverse Reaction Terms. In: Stephens M.D.B., Talbot J.C.C., Routledge P.A., editors. The Detection of New Adverse Reactions. Macmillan Reference; London, UK: 1998. pp. 32–44.

10. EuroQol Research Foundation EQ-5D-5L User Guide. 2019.

11. World Health Organization Cardiovascular Diseases. 2021.

12. U.S. Department of Health and Human Services. Food and Drug Administration. CDER. CBER. CDRH. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Food and Drug Administration; Rockville, MD, USA: 2009.

13. Cipolle R.J., Strand L.M., Morley P.C. Pharmaceutical Care Practice: The Patient Centered Approach to Medication Management. 3rd ed. McGraw-Hill; New York, NY, USA: 2012.

14. Schweikert B., Hunger M., Meisinger C., König H.-H., Gapp O., Holle R. Quality of Life Several Years after Myocardial Infarction: Comparing the MONICA/KORA Registry to the General Population. European Heart Journal. 2009;30:436–443.

15. Centers for Disease Control and Prevention. Measuring Healthy Days. CDC; Atlanta, GA, USA: 2000.

16. Leendertse A.J., de Koning G.H.P., Goudswaard A.N., Belitser S.V., Verhoef M., de Gier H.J., Egberts A.C.G., van der Bemt P.M.L.A. Preventing Hospital Admissions by Reviewing Medication (PHARM) in Primary Care: An Open Controlled Study in an Elderly Population. Journal of Clinical Pharmacy and Therapeutics. 2013;38:379–387.

17. Chan M., Nicklason F., Vial J.H. Adverse Drug Events as a Cause of Hospital Admission in the Elderly. Internal Medicine Journal. 2001;31:199–205.

18. OECD/European Union. Health at a Glance: Europe 2020: State of Health in the EU Cycle. OECD Publishing; Paris, France: 2020.

19. Levine D.M., Linder J.A., Landon B.E. The Quality of Outpatient Care Delivered to Adults in the United States, 2002 to 2013. JAMA Internal Medicine. 2016;176:1778–1790.

20. Mohammed M.A., Moles R.J., Chen T.F. Impact of Pharmaceutical Care Interventions on Health-Related Quality-of-Life Outcomes: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy. 2016;50:862–881.

21. World Health Organization. Constitution of the World Health Organization. WHO; Geneva, Switzerland: 1948.

22. Lenaghan E., Holland R., Brooks A. Home-Based Medication Review in a High Risk Elderly Population in Primary Care—The POLYMED Randomised Controlled Trial. Age and Ageing. 2007;36:292–297.

23. Mohammed A.M., Moles R.J., Chen T.F. Pharmaceutical Care and Health Related Quality of Life Outcomes over the Past 25 Years: Have We Measured Dimensions That Really Matter? International Journal of Clinical Pharmacy. 2018;40:3–14.

24. Hepler C.D., Strand L.M. Opportunities and Responsibilities in Pharmaceutical Care. American Journal of Hospital Pharmacy. 1990;47:533–543.

25. Batóg P., Rencz F., Péntek M., Gulácsi L.G., Filipiak K.J., Prevolnik Rupel V., Simon J., Brodszky V., Baji P., Závada J., et al. EQ-5D Studies in Cardiovascular Diseases in Eight Central and Eastern European Countries: A Systematic Review of the Literature. Kardiologia Polska. 2018;76:860–870.

26. Tommelein E., Mehuys E., van Hees T., Adriaens E., van Bortel L., Christiaens T., van Tongelen I., Remon J.-P., Boussery K., Brusselle G. Effectiveness of Pharmaceutical Care for Patients with Chronic Obstructive Pulmonary Disease (PHARMACOP): A Randomized Controlled Trial. British Journal of Clinical Pharmacology. 2014;77:756–766.

27. Johnson J.A., Bootman J.L. Drug-Related Morbidity and Mortality and the Economic Impact of Pharmaceutical Care. American Journal of Health-System Pharmacy. 1997;54:554–558.

28. Schröder S., Martus P., Odin P., Schaefer M. Impact of Community Pharmaceutical Care on Patient Health and Quality of Drug Treatment in Parkinson’s Disease. International Journal of Clinical Pharmacy. 2012;34:746–756.

29. Brajković A., Mucalo I., Vidović T., do Nascimento M.M.G., Balenović A., Protrka I., Ramalho de Oliveira D. Implementation of Medication Management Services at the Primary Healthcare Level—A Pilot Study. Acta Pharmaceutica. 2019;69:585–606.

30. del Pozzo-Magaña B.R., Rieder M.J., Lazo-Langner A. Quality of Life in Children with Adverse Drug Reactions: A Narrative and Systematic Review. British Journal of Clinical Pharmacology. 2015;80:827–833.

31. Devlin N.J., Parkin D., Browne J. Patient-Reported Outcome Measures in the NHS: New Methods for Analysing and Reporting EQ-5D Data. Health Economics. 2010;19:886–905.

32. Siette J., Dodds L., Seaman K., Wuthrich V., Johnco C., Earl J., Dawes P., Westbrook J.I. The impact of COVID-19 on the quality of life of older adults receiving community-based aged care. Australasian Journal on Ageing. 2021;40:84–89.

33. Rotta I., Salgado T.M., Felix D.C., Souza T.T., Correr C.J., Fernandez-Llimos F. Ensuring Consistent Reporting of Clinical Pharmacy Services to Enhance Reproducibility in Practice: An Improved Version of DEPICT. Journal of Evaluation in Clinical Practice. 2015;21:548–590.

Downloads

Published

2024-09-30

How to Cite

Dhaifalla M. Moparak Alrwili, Mohammed Tajir D Alanazi, Muqrin Saeed Hulayyil Almutairi, Alharbi Waleed Abdullah M, Salam Saud Alanazi, Mohammed Hassan Almuntashiri, … Hamdi Ayidh Qidan Albaqami. (2024). Impact of Pharmacist-Led Medication Review on Reducing Adverse Drug Events. International Journal of Computational and Experimental Science and Engineering, 10(4). https://doi.org/10.22399/ijcesen.4646

Issue

Vol. 10 No. 4 (2024): IJCESEN

Section

Research Article

License

Copyright (c) 2024 International Journal of Computational and Experimental Science and Engineering

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.